News & Articles
Discover our latest news features, insightful blog posts, and important updates from AuctuCel.
AuctuCel Launches AuctuPrime, Advancing Safer and More Scalable Cell Therapy Manufacturing
Removing animal serum and human platelet supplements to unlock a new era of safer, more consistent and scalable cell therapy manufacturing. KUALA LUMPUR, Malaysia – 24 July 2026 — Behind every breakthrough cell therapy is a manufacturing process few patients ever see—but one that ultimately determines whether these treatments can reach the people who need them. While cell therapies are transforming the treatment of cancer, autoimmune diseases and degenerative disorders, manufacturing remains one of the industry's greatest challenges. Current production processes frequently rely on animal serum and donor-derived human platelet supplements, introducing variability, supply constraints and manufacturing complexity that limit scalability and broader clinical adoption.
AuctuCel Expands into South Korea Through Partnership with JCBIO to Advance Biomanufacturing
Strategic partnership marks AuctuCel's expansion beyond Southeast Asia, with an initial focus on supporting South Korea's cell therapy ecosystem SINGAPORE / SEOUL, South Korea – 30 July 2026 – AuctuCel Pte Ltd, a Singapore biotechnology company specialising in AI-powered bioprocess technologies and advanced cell culture media, today announced a strategic partnership with JCBIO , one of South Korea's leading biotechnology companies. Through the partnership, JCBIO will distribute AuctuCel's cell therapy culture media in South Korea, strengthening access to high-quality culture media solutions for researchers, biotechnology companies and cell therapy developers. While the partnership will initially focus on cell therapy applications, it also reflects AuctuCel's broader vision of advancing next-generation biomanufacturing through innovative cell culture solutions. The partnership marks AuctuCel's expansion beyond Southeast Asia into one of the world's leading biotechnology markets. South Korea is internationally recognised for its vibrant biotechnology ecosystem, world-class research institutions and strong leadership in cell therapy and regenerative medicine, making it a strategic market for AuctuCel's continued global growth. "Our partnership with JCBIO represents an important milestone asAuctuCel expands beyond Southeast Asia into one of the world's leading biotechnology markets," said Dr Chee Wai Fhu , Chief Executive Officer of AuctuCel. "Our current focus is supporting South Korea's growing cell therapy ecosystem, while building long-term collaborations that advance next-generation biomanufacturing through innovative cell culture solutions."
AuctuCel Wins Emerging Bioprocessing Supplier Award at Asia-Pacific Biopharma Excellence Awards 2026
AuctuCel is honoured to be recognised by the biopharma community as the Winner of the Emerging Bioprocessing Supplier Award at the Asia-Pacific Biopharma Excellence Awards 2026, organised by IMAPAC. “This recognition means a great deal to our team and reflects our continued commitment to serving the industry,” said the AuctuCelc Biopharma Excellence Awards celebrates outstanding achievements across the Asian biopharma sector, and AuctuCel is humbled to be recognised alongside many respected leaders and established companies in the industry. “This recognition means a great deal to our team and reflects our continued commitment to serving the industry,” said the AuctuCel team.
AuctuCel Establishes First Distribution Centre in China to Strengthen Regional Supply Chain
Singapore / China — January 2026 AuctuCel, a Singapore-based biotechnology company spun out of A*STAR’s Bioprocessing Technology Institute, has announced the establishment of its first distributioncentre in China , marking a key milestone in the company’s regional expansion. The new distribution centre strengthens AuctuCel’s ability to support customers across China and the wider Asia region , enabling shorter lead times , greater supply consistency , and improved regional responsiveness . This development reinforces the company’s commitment to building a reliable and scalable supply chain as demand for its products continues to grow.
AuctuCel Signs MOU with StellarCell Bio to Advance Exosome and Cell Culture Research
(From left) Mr. Zhou, Chief Strategy Officer of StellarCell Bio; Ms. Guo, General Manager of StellarCell Bio; together with Dr Fhu Chee Wai, Co-founder and Chief Executive Officer of AuctuCel, and Dr Zach Pang, Co-founder and Chief Scientific Advisor of AuctuCel, at the MOU signing ceremony to strengthen collaboration in cell culture and bioprocess optimisation. We’re pleased to share that AuctuCel has signed an MOU with StellarCell BioMedicine Inc. (星誠細胞生醫) , a Taiwan-based company focused on regenerative medicine and cell therapy. Under this collaboration, AuctuCel will provide our serum-free and xeno-free specialised media to support StellarCell Bio’s exosome and extracellular vesicle (EV) culture research. Research outcomes will be shared between both teams, with the potential for joint publications. Where needed, we will also support culture media optimisation to meet performance requirements.
Syarikat Spin-off A*STAR BTI, AuctuCel lancar platform AI
Mengurangkan kos pembangunan sehingga 80 peratus, mempercepatkan garis masa sebanyak 83 peratus serta meningkatkan produktiviti sel lebih 20 peratus. SINGAPURA, 12 September 2025 – AuctuCel, syarikat bioteknologi baharu hasil spin-off daripada A*STAR Bioprocessing Technology Institute (BTI) melancarkan platform proprietari dikenali sebagai Fluxperior iaitu satu sistem berkuasa kecerdasan buatan (AI) yang dibangunkan bagi mengurangkan kos dan masa dalam menghasilkan resipi nutrien untuk pertumbuhan sel yang digunakan dalam rawatan perubatan. Dibangunkan oleh penyelidik A*STAR BTI, Fluxperior menggabungkan pemodelan komputer dengan AI untuk meramal keperluan nutrien sel secara tepat, sekali gus menggantikan kaedah tradisional berasaskan proses cuba jaya yang kebiasaannya mengambil masa lebih enam bulan. Hasil kajian menunjukkan Fluxperior mampu mengurangkan kos pembangunan sehingga 80 peratus, mempercepatkan garis masa sebanyak 83 peratus serta meningkatkan produktiviti sel lebih 20 peratus.
